Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)
Completed
Conditions studied: High Risk Cancer
In brief
This is a Multinational, Multicenter, retrospective study for the evaluation of the standalone efficacy and safety of an Artificial Intelligence/Machine Learning (AI/ML) technology-based end-to-end Computer assisted Detection/Computer Assisted Diagnosis (CADe/CADx) Software as a Medical Device (SaMD) developed to detect, localize and characterize malignant, and suspicious for lung cancer nodules on Low Dose Computed Tomography (LDCT) scans taken as part of a Lung Cancer Screening (LCS) program. LDCT Digital Imaging and Communications in Medicine (DICOM) images of patients who underwent lung cancer screening were selected and included into the study. Selected scans will then be analyzed by the CADe/CADx SaMD and compared to radiologist generated reference standards including lesions localization and lesion cancer diagnosis. Figures of merit at patient level and lesion level detection and diagnostic efficacy will be calculated as well as sub-class analysis to ensure algorithm performance generalizability.
Key facts
- Study ID
- NCT06576232
- Run by
- Median Technologies
- People needed
- 1147
- Starts
- 2022-09-21
- Expected to finish
- 2024-08-21
- Last updated by the study team
- 2024-08-28
Who can join
Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- ≥50-80 Years of age;
- Current or ex-smoker (>=20 pack years);
- Patient screened and surveilled for lung cancer screening following lung cancer screening guidelines (equivalent to United States Preventive Services Task Force (USPSTF) 2021 Criteria);
- Received LDCT due to inclusion in high-risk category for lung cancer.
You may not qualify if…
- Prior lung resection;
- Pacemaker or other indwelling metallic medical devices in the thorax that interfere with CT acquisition;
- Patients/images used during AI model development;
- Patients with only hilar and/or mediastinal cancer(s);
- Patients with only ground glass cancer(s);
- Patients with nodules, solid or part-solid >30mm (masses);
- Patients that are not accompanied with the required clinical information;
- Patients with imaging with any of the following: missing slices, slice thickness >3mm;
- Partial cover of the lung.
Where it is running
- University of Pennsylvania - Penn Center for Innovation — Philadelphia, Pennsylvania, United States
- Baptist Clinical Research Institute — Memphis, Tennessee, United States
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States
- Fundacion instituto de investigacion sanitaria de la fundacion jimenez diaz (FJD) — Madrid, Spain
- Universidad de Navarra — Pamplona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.